07:00 , Oct 20, 2016 |  BC Innovations  |  Product R&D

Sirtuins forge ahead

Since sirtuins hit the scene as modulators of numerous cellular pathways over 20 years ago, the enzymes have been implicated in metabolic diseases, aging and cancer. Now Forge Life Science LLC has licensed findings from...
07:00 , Mar 24, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Sirtuin 2 (SIRT2); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc)

Cancer INDICATION: Breast cancer In vitro, cell and mouse studies identified a thioacyl lysine-based SIRT2 inhibitor that could help treat breast cancer. Chemical synthesis and in vitro testing of thioacyl lysine analogs identified a compound...
08:00 , Nov 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma Sirtuin 1 (SIRT1); SIRT2 Cell culture and zebrafish studies suggest inhibiting SIRT1 could help treat metastatic Ewing's sarcoma. In tumor samples from patients with...
07:00 , Aug 15, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Crystal structures of sirtuin 1 (SIRT1), SIRT2 and SIRT3 bound to inhibitors Crystal structures of sirtuins bound to inhibitors could guide the development of compounds...
07:00 , Apr 25, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Highly potent inhibitors of sirtuin 1 (SIRT1), SIRT2 and SIRT3 Thieno[3,2-d]pyrimidine-6-carboxamide-based sirtuin inhibitors could be used as research compounds to probe the functions of SIRT1,...
08:00 , Jan 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury Sirtuin 2 (SIRT2) Mouse studies suggest inhibiting SIRT2 could help treat ischemia/reperfusion injury. In a mouse model of...
07:00 , Sep 20, 2012 |  BC Innovations  |  Targets & Mechanisms

ASIRTaining a Parkinson's disease target

A Tufts University team has compelling evidence that reducing sirtuin 2 activity could be beneficial in Parkinson's disease. 1 The findings argue for developing brain-penetrating sirtuin 2 inhibitors. Sirtuin 2 ( SIRT2 ) is one...
07:00 , Sep 20, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Sirtuin 2 (SIRT2) Mouse studies suggest antagonizing SIRT2 could be useful for treating PD. In a mouse model of dopaminergic neurotoxin-induced PD,...
07:00 , Jun 28, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD); Huntington's disease (HD) Sirtuin 2 (SIRT2) A SAR study identified SIRT2 inhibitors that could be useful for treating...
07:00 , May 14, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Sirtuin 1 (SIRT1) An SAR study identified a series of acetylated lysine analogs as SIRT1 inhibitors that could help treat...